Hologic Company Profile (NASDAQ:HOLX)

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

Hologic, Inc. (NASDAQ:HOLX) announced its quarterly earnings data on Wednesday, August, 2nd. The company reported $0.50 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.49 by $0.01. The company had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. Hologic's quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.51 EPS. View Hologic's Earnings History.

Hologic is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Hologic.

Hologic issued an update on its fourth quarter earnings guidance on Wednesday, August, 2nd. The company provided EPS guidance of $0.48-0.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.50. The company issued revenue guidance of $785-800 million, compared to the consensus revenue estimate of $817.04 million.

13 brokerages have issued 1-year target prices for Hologic's stock. Their predictions range from $42.00 to $53.00. On average, they expect Hologic's stock price to reach $48.38 in the next year. View Analyst Ratings for Hologic.

Here are some recent quotes from research analysts about Hologic stock:

• 1. According to Zacks Investment Research, "Hologic’s third-quarter 2017 performance was quite promising with revenues and earnings beating the Zacks Consensus Estimate. The company’s top-line growth was led by strength in the molecular diagnostics and GYN Surgical businesses. Moreover, sales were driven by the company’s recent receipt of CE mark for its new Panther Fusion system and Panther Fusion assays for flu and respiratory testing. Also, the company’s strong cash position is another encouraging factor. On the flip side, Hologic has been trading below the broader industry over the last six months. Moreover, the lowered guidance suggests dull prospects. Furthermore, the blood screening divestiture is expected to impede the company’s growth momentum in the days ahead. Foreign currency headwinds and a competitive landscape also continue to pose challenges." (8/4/2017)
• 2. Needham & Company LLC analysts commented, "FDA’s latest monthly Mammography Quality Standards Act (MQSA) statistics were published on 8/1/17. The number of digital breast tomosynthesis (DBT) units increased by 106 during July which represents a (2.8%) Y/ Y decrease and a 2.2% sequential increase. DBT unit penetration increased to 27.4% from 27.0% last month and facility penetration increased to 40.8% from 40.0% last month. While this is a bit of an improvement from last month, the MQSA data seems to indicate that the slower Breast Imaging growth seen in F2Q17 has continued. We note that HOLX’s 3D mammography sales are less than 13% of its sales." (8/1/2017)

Hologic saw a decline in short interest in August. As of August 15th, there was short interest totalling 8,374,534 shares, a decline of 13.8% from the July 31st total of 9,718,730 shares. Based on an average daily volume of 5,293,594 shares, the days-to-cover ratio is presently 1.6 days. Approximately 3.0% of the shares of the stock are sold short.

Some companies that are related to Hologic include Waters Corporation (WAT), ResMed (RMD), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Quidel Corporation (QDEL), Accelerate Diagnostics (AXDX), Mazor Robotics (MZOR), Natus Medical Incorporated (BABY), ABAXIS (ABAX), Luminex Corporation (LMNX), LeMaitre Vascular (LMAT), Pacific Biosciences of California (PACB), GenMark Diagnostics (GNMK), Accuray Incorporated (ARAY) and ViewRay (VRAY).

Hologic's management team includes the folowing people:

• Stephen P. MacMillan, Chairman of the Board, President, Chief Executive Officer
• Robert W. McMahon, Chief Financial Officer
• Sanjay Prabhakaran, Regional President - Asia
• Peter J. Valenti III, Division President- Breast and Skeletal Health
• Jan Verstreken, Regional President - Europe,Middle EastandAfrica(EMEA) and Canada
• Thomas A. West, Division President- Diagnostics
• Eric B. Compton, Chief Operating Officer
• Michael J. Watts, Vice President, IR Contact Officer
• John M. Griffin, General Counsel
• Elaine S. Ullian, Lead Independent Director

Hologic's stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.53%), State Street Corp (4.52%), Capital Research Global Investors (3.23%), Capital World Investors (2.45%), Victory Capital Management Inc. (1.79%) and Bank of Montreal Can (1.22%). Company insiders that own Hologic stock include David R Lavance Jr, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Nancy Leaming, Peter J Valenti III and Sally Crawford. View Institutional Ownership Trends for Hologic.

Hologic's stock was sold by a variety of institutional investors in the last quarter, including Pioneer Investment Management Inc., Capital Research Global Investors, Schwab Charles Investment Management Inc., Voya Investment Management LLC, Prudential Financial Inc., Smith Asset Management Group LP, TIAA CREF Investment Management LLC and Teachers Advisors LLC. Company insiders that have sold Hologic stock in the last year include Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Peter J Valenti III and Sally Crawford. View Insider Buying and Selling for Hologic.

Hologic's stock was acquired by a variety of institutional investors in the last quarter, including Capital World Investors, HealthCor Management L.P., Columbus Circle Investors, Vanguard Group Inc., Koch Industries Inc., Victory Capital Management Inc., Russell Investments Group Ltd. and Alliancebernstein L.P.. View Insider Buying and Selling for Hologic.

Shares of Hologic can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Hologic stock can currently be purchased for approximately $37.57.